Adriblastin fast dissolving powder 50mg doxorubicin Cancer Адрибластин

Adriblastin Indications

To alleviate symptoms in a number of neoplastic pathologies, including the treatment of breast, lung, bladder, thyroid and ovaries; osteosarcoma and soft tissue sarcoma, non-Hodgkin and Hodgkin lymphoma, neuroblastoma, Wilms' tumor, acute lymphoblastic leukemia and acute myeloid leukemia. Adryblastyn detects a positive effect in the case of superficial bladder cancer with the drug administered as intravezykalnomu after transurethral resection (preventive treatment) and for therapeutic purposes.

Also obtained positive results in treating other types of solid tumors, but the experience of the drug is still very limited justification for its particular indication.

Contradictions

- persistent myelosuppression;
- severe hepatic insufficiency;
- recently transferred myocardial infarction;
- severe arrhythmia;
- severe heart failure;
- preliminary treatment with maximal cumulative doses of doxorubicin, daunorubicin, epyrubicin, idarubicin and / or other anthracyclines and anthracenzenes.
- urinary tract infection;
- inflammation of the bladder;
- hematuria

Dosage & Administration

Recommended dose is 60-75 mg / m2 body surface.

Used by intravenous infusion at a 21-day interval, taking into account the condition of the patient's blood and bone marrow.